Biotech, pharma, and VCs invest in new technologies to drive future growth

artificial_intelligence_ai_large

A feature analyzing the recent investment activity in digital technologies and AI.

As healthcare systems undergo a digital transformation, the biopharma industry has begun to harness the power of new technologies such as artificial intelligence (AI) and digital tools, to improve research and development (R&D) and processes, and enhance stakeholder engagement to drive product adoption and revenue generation. Market researchers forecast that the pharma industry will spend up to $4.5 billion investing in the digital transformation of pharmaceutical manufacturing facilities by 2030 and spending on AI alone could exceed $3 billion by 2025 as companies use this technology to personalize treatment, facilitate data handling and analytics to generate actionable insights and drive outcome-based care.

According to Deloitte, some digital technologies such as the cloud (49%), AI (38%), data lakes (33%), and wearables (33%) have been widely adopted by the industry in day-to-day operations whereas others such as quantum computing and digital twins have yet to gain traction. Increasingly, biopharma views digital innovation as a competitive differentiator and it has the potential to transform activities across the whole of the biopharma supply chain to deliver patient-centered and seamless drug development and commercialization.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical